Considering the Experimental Use of Temozolomide in Glioblastoma Research

Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient’s survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damag...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Biomedicines
Glavni autori: Herbener, Verena J., Burster, Timo, Goreth, Alicia, Pruss, Maximilian, von Bandemer, Hélène, Baisch, Tim, Fitzel, Rahel, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew, Strobel, Hannah
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7344626/
https://ncbi.nlm.nih.gov/pubmed/32512726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8060151
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items